Organic compounds

India Ethylene Vinyl Acetate (EVA) (Comprehensive Techno-Commercial) Market Analysis & Forecasts, 2013-2018, 2019 & 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 5, 2019

The "India Ethylene Vinyl Acetate (EVA) (Comprehensive Techno-Commercial) Market Analysis, 2013-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Ethylene Vinyl Acetate (EVA) (Comprehensive Techno-Commercial) Market Analysis, 2013-2030" report has been added to ResearchAndMarkets.com's offering.
  • The Ethylene Vinyl Acetate (EVA) demand in India stood at 178 KTPA in 2019 and is expected to grow at a healthy CAGR during the forecast period.
  • This demand can be attributed to the growing need for high impact strength-based product having crack resistant ability and tough nature etc.
  • Hence, to fulfill the total market demand for EVA, India imports it from other global EVA manufacturers countries such as South Korea, Thailand, Belgium, Taiwan, France etc.

Global $6.7 Bn Ovarian Cancer Opportunity Analysis and Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 5, 2019

The "Ovarian Cancer: Opportunity Analysis and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ovarian Cancer: Opportunity Analysis and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The dramatic growth in the ovarian cancer market is largely attributed to the label expansions for PARP inhibitors such as Lynparza, Zejula and Rubraca.
  • In 2028, three PARP inhibitor drugs are expected to have combined revenue of $2.8bn, constituting more than 40% of the global ovarian cancer market.
  • Analysis of the current and future market competition in the global ovarian cancer market.

Adamis Pharmaceuticals Provides Regulatory Update for Its Higher Dose Naloxone Pre-Filled Syringe

Retrieved on: 
Tuesday, November 5, 2019

Adamis intends to make an announcement relating to FDA action concerning the NDA after it receives a notice of action or similar communication from the agency.

Key Points: 
  • Adamis intends to make an announcement relating to FDA action concerning the NDA after it receives a notice of action or similar communication from the agency.
  • ZIMHI is a high-dose naloxone injection product candidate intended for the treatment of opioid overdose.
  • Naloxone is an opioid antagonist and is generally considered the drug of choice for immediate administration for opioid overdose.
  • Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose.

Neurocrine Biosciences Reports Third Quarter 2019 Financial Results

Retrieved on: 
Monday, November 4, 2019

In further connection with the Voyager collaboration, the Company recognized IPR&D of $118.1 million during the first nine months of 2019.

Key Points: 
  • In further connection with the Voyager collaboration, the Company recognized IPR&D of $118.1 million during the first nine months of 2019.
  • AbbVie initiated a Phase II study of elagolix in women with polycystic ovary syndrome (PCOS) during the third quarter of 2019.
  • Neurocrine Biosciences will hold a live conference call and webcast today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
  • Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.

Puma Biotechnology to Present at the Credit Suisse Healthcare Conference

Retrieved on: 
Monday, November 4, 2019

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:55 a.m. MST (9:55 a.m. PST, 12:55 p.m. EST) on Tuesday, November 12, at the Credit Suisse 28th Annual Healthcare Conference.

Key Points: 
  • Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:55 a.m. MST (9:55 a.m. PST, 12:55 p.m. EST) on Tuesday, November 12, at the Credit Suisse 28th Annual Healthcare Conference.
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
  • Puma in-licenses the global development and commercialization rights to three drug candidates PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
  • NERLYNX is a registered trademark of Puma Biotechnology, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20191104005169/en/

Atacand - Drug Insight Study 2019 with Worldwide Sales Forecasted to 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 4, 2019

The "Atacand- Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Atacand- Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Atacand Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • The report covers the Global Market Assessment of the Atacand covering the historical global sales and also provides the Atacand sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Atacand and emerging therapies in this space.

ChildLife Essentials® Liquid Vitamin C wins Taste for Life 2019 Immunity Essentials Award

Retrieved on: 
Monday, November 4, 2019

EL SEGUNDO, Calif., Nov. 4, 2019 /PRNewswire/ -- ChildLife Essentials, the best nutritional liquid supplements for infants and children developed by Dr. Murray Clarke, announced today that ChildLife Essentials Liquid Vitamin C is a winner of Taste for Life 2019 Immunity Essentials Awards .

Key Points: 
  • EL SEGUNDO, Calif., Nov. 4, 2019 /PRNewswire/ -- ChildLife Essentials, the best nutritional liquid supplements for infants and children developed by Dr. Murray Clarke, announced today that ChildLife Essentials Liquid Vitamin C is a winner of Taste for Life 2019 Immunity Essentials Awards .
  • Vitamin C, an immune support superstar, has been thoroughly researched and shown to help support the immune system through daily use.
  • Our ChildLife Essentials Liquid Vitamin C is a natural orange flavor and will have your children asking for it every day.For immune support and environmental protection, we recommend using ChildLife Essentials Liquid Vitamin C daily as a vital antioxidant.
  • "We are very honored to be recognized by Taste for Life 2019 Immunity Essentials Awards for our ChildLife Essentials Liquid Vitamin C," said Karyn McCarthy, VP of Sales + Marketing at ChildLife Essentials.

Cellulose Acetate Market to Reach USD 6.33 Billion by 2026 | Reports And Data

Retrieved on: 
Monday, November 4, 2019

NEW YORK, Nov. 4, 2019 /PRNewswire/ -- The global cellulose acetate market is forecast to reach USD 6.33 Billion by 2026, according to a new report by Reports and Data.

Key Points: 
  • NEW YORK, Nov. 4, 2019 /PRNewswire/ -- The global cellulose acetate market is forecast to reach USD 6.33 Billion by 2026, according to a new report by Reports and Data.
  • Cellulose acetate is a semi-synthetic compound which is manufactured from purified natural cellulose.
  • The market for cellulose acetateis influenced by the rising number of cigarette consumers all over the world.
  • Consistent advancements in the cellulose acetate market owing to innovative efforts have enhanced the efficiency of cellulose acetate.

Cellulose Acetate Market to Reach USD 6.33 Billion by 2026 | Reports And Data

Retrieved on: 
Monday, November 4, 2019

Cellulose Acetate Market Size USD 4.11 Billion in 2018, Market Growth - CAGR of 5.6%, Cellulose Acetate Industry Trends Preference for eco-friendly acetate filter tow with enhanced biodegradability

Key Points: 
  • Cellulose Acetate Market Size USD 4.11 Billion in 2018, Market Growth - CAGR of 5.6%, Cellulose Acetate Industry Trends Preference for eco-friendly acetate filter tow with enhanced biodegradability
    NEW YORK, Nov. 4, 2019 /PRNewswire/ -- The global cellulose acetate market is forecast to reach USD 6.33 Billion by 2026, according to a new report by Reports and Data.
  • Cellulose acetate is a semi-synthetic compound which is manufactured from purified natural cellulose.
  • The market for cellulose acetateis influenced by the rising number of cigarette consumers all over the world.
  • Consistent advancements in the cellulose acetate market owing to innovative efforts have enhanced the efficiency of cellulose acetate.

MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics

Retrieved on: 
Monday, November 4, 2019

WESTLAKE VILLAGE, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil.
  • Treprostinil Technosphere (TreT) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension.
  • Pursuant to the agreement, MannKind is eligible to earn additional milestone payments up to $25 million upon the achievement of other defined development milestones.
  • MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.